Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma a First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Abhijeet Kumar
Sponsor
IQVIA RDS Inc.
Unit
Cancer Center Division